3 min read
In Novo Nordisk A/S & Anor v British Telecommunications & Ors [2026] EWHC 1094 (Ch), the High Court granted what is understood to be the first website blocking injunction to stop the marketing and sale of counterfeit and unlicensed prescription-only medicines.
The decision is encouraging for pharmaceutical companies and provides a precedent for stopping the sale of potentially dangerous and unlicensed medicine.
Novo Nordisk applied for a website blocking injunction to prevent access to four websites (the “Target Websites”) selling and supplying unlicensed and counterfeit versions of its prescription-only diabetes and weight-loss medicines.
Novo Nordisk owns extensive intellectual property rights relating to these products, including trade mark registrations for OZEMPIC, RYBELSUS and WEGOVY. Novo Nordisk also has the exclusive right to supply Semaglutide products in the UK and will do so until patent/SPC expiry in 2031.
The bases on which Novo Nordisk requested the blocking order were:
Trade mark infringement;
Passing off; and
Breaches of the Human Medicines Regulations 2012.
The evidence showed that the Target Websites used Novo Nordisk’s registered trade marks to sell counterfeit and unlicensed semaglutide products and misled customers into believing that the products were supplied or licensed by Novo Nordisk.
There was also evidence that the Target Websites were breaching the Human Medicines Regulations 2012, including by selling medicinal products without the required marketing authorisation and supplying prescription-only medicines without a prescription.
The defendants were major UK ISPs, including BT, Sky, Virgin Media and TalkTalk. Their role was essentially that of an intermediary providing internet access to UK consumers.
Website operators engaged in counterfeiting activities are often anonymous, based overseas, or otherwise difficult to identify and pursue directly. As a result, rights holders frequently seek orders against ISPs, requiring them to prevent users in the UK from accessing the offending websites.
The threshold requirements for a blocking injunction against ISPs are:
The ISPs are acting as intermediaries;
The users or operators of the websites are infringing the claimant’s trade marks or committing a legal wrong;
The users or operators of the websites must be using the ISPs’ services; and
The ISPs must have actual knowledge of the wrongdoing.
The court found that these requirements were met. The ISPs acted as intermediaries, their services were used to facilitate the infringement, and the evidence filed with the application gave them actual knowledge of the wrongdoing.
Importantly, the court did not find that the ISPs themselves were liable for trade mark infringement, passing off or breaches of the Human Medicines Regulations. Instead, the ISPs were considered to be intermediaries whose services were being used to facilitate the wrongdoing. The purpose of the injunction was therefore preventative rather than punitive.
In order for the court to grant a blocking order, it must be satisfied that it is proportionate. In this case, the risks to public health were central to the decision to grant the blocking order.
Novo Nordisk relied on evidence previously submitted in the US about deaths and injuries that had been linked to the use of counterfeit semaglutide products. Novo Nordisk also relied on evidence from the World Health Organisation which had previously warned that substandard and counterfeit medicines can cause as many as 1 million excess deaths annually.
Novo Nordisk also submitted British press reports linking counterfeit semaglutide products to serious health problems and hospitalisations.
The court held that a blocking order would be a highly effective way of combatting the dangers posed by the sale of these counterfeit medicines. Previous blocking orders showed that on average, websites targeted by blocking orders attracted 98% fewer UK visitors. By contrast, individual takedown requests can create a ‘whack-a-mole’ problem, with websites reappearing shortly after removal.
All of these were considered legitimate reasons to conclude that the blocking order sought was a proportionate remedy to deal with both the trade mark infringement and the criminal acts under the Human Medicines Regulations 2012.
Website blocking orders have been used for many years in cases involving copyright infringement, such as online piracy, and later in trade mark cases involving the sale of counterfeit consumer goods. What makes this case unusual is that it is the first reported case in which the court has ordered UK internet service providers to block access to websites selling counterfeit and unlicensed prescription-only medicines.
The case therefore extends an established enforcement tool into a new area where intellectual property and public health concerns overlap. The court recognised that the Target Websites were not merely infringing trade mark rights but also involved regulatory breaches and criminal offences under the Human Medicines Regulations 2012.
This was particularly important because evidence before the court showed that the websites were selling counterfeit and unlicensed medicines to UK consumers and that some products may have posed significant health risks. The Medicines and Healthcare products Regulatory Agency (MHRA) had also been unable to secure the removal of some of the websites through its own enforcement efforts.
The decision provides pharmaceutical companies with another potential enforcement option where counterfeit or unlicensed medicines are being sold online. In circumstances where website operators cannot easily be located or where traditional takedown efforts have been unsuccessful, a blocking order may offer a practical way of reducing consumer access to unlawful websites.
Jamie is an associate trade mark attorney and a member of the firm’s trade mark team. His interests are in contentious trade mark work, copyright and media law, having completed optional modules in these areas at university. He has previously worked as an IP assistant for a MedTech firm, assisting with contentious matters in patent law, contract law and trade secrets. He has also helped manage the firm’s IP portfolio.
Email: jamie.emerick@mewburn.com
Stay up to date with our latest thinking.